Karyopharm Therapeutics Appoints Zhen Su to its Board
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Zhen Su, MD, MBA, to its Board of...
Neutral
or
Karyopharm News & Analysis
-
-
Morgan Stanley maintains Karyopharm at 'equalweight' with a price target of $4.00
An analyst from Morgan Stanley maintained Karyopharm (NASDAQ: KPTI) at 'equalweight' with a price target of $4.00 from a prior price target of $5.00. Prior to this rating, Karyopharm had 5...
-
RBC Capital maintains Karyopharm at 'outperform' with a price target of $4.00
An analyst from RBC Capital maintained Karyopharm (NASDAQ: KPTI) at 'outperform' with a price target of $4.00 from a prior price target of $5.00. Prior to this rating, Karyopharm had 6 buy...
-
Karyopharm earnings beat by $0.05, revenue topped estimates
Investing.com - Karyopharm (NASDAQ: KPTI) reported second quarter EPS of $-0.29, $0.05 better than the analyst estimate of $-0.34. Revenue for the quarter came in at $37.6M versus the...
-
Wedbush maintains Karyopharm at 'neutral' with a price target of $4.00
An analyst from Wedbush maintained Karyopharm (NASDAQ: KPTI) at 'neutral' with a price target of $4.00 from a prior price target of $7.00. Prior to this rating, Karyopharm had 6 buy...
-
Karyopharm Therapeutics Presentation of Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer
Karyopharm Therapeutics (NASDAQ:KPTI) Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the presentation of updated...
-
Why Are Karyopharm Therapeutics Shares Gaining Today?
Karyopharm Therapeutics Inc (NASDAQ: KPTI) shares are trading higher after the FDA granted Fast Track Designation to the development program of selinexor for myelofibrosis, including primary...
-
After-hours movers: Masimo sinks on Q2 warning, Pinterest gains on upgrade
After-Hours Movers: Masimo Corp (NASDAQ:MASI) 24% LOWER; expects its consolidated revenue for the second quarter 2023 to range from $453 million to $457M, versus the consensus of...
-
Karyopharm Therapeutics Granted FDA Fast Track Designation for Selinexor
Karyopharm Therapeutics (NASDAQ:KPTI) Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the United States Food and Drug...
-
Karyopharm Therapeutics Initiates Pivotal Phase 3 Study of XPO1 Inhibitor Selinexor and Ruxolitinib in JAK Inhibitor (JAKi) Naïve Myelofibrosis
Karyopharm Therapeutics (NASDAQ:KPTI) Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the initiation of a pivotal Phase 3...
-
RBC Capital maintains Karyopharm at Outperform, PT $5.00
A RBC Capital analyst maintained Karyopharm (NASDAQ: KPTI) at Outperform and a price target of $5.00 from a prior price target of $6.00. Prior to this rating, Karyopharm had 6 buy...
-
Karyopharm earnings beat by $0.07, revenue topped estimates
Investing.com - Karyopharm (NASDAQ: KPTI) reported first quarter EPS of $-0.30, $0.07 better than the analyst estimate of $-0.37. Revenue for the quarter came in at $38.7M versus the...
-
Karyopharm Therapeutics Presents Updated Phase 1 Selinexor Data
Karyopharm Therapeutics (NASDAQ:KPTI) Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced updated results from the Phase 1 study...
-
DiaMedica Therapeutics Appoints Tanya Lewis to Its Board
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today...
-
Karyopharm and Menarini Granted Full Marketing Authorization for NEXPOVIO in Combination with Bortezomib and Dexamethasone in the UK
Karyopharm Therapeutics Inc. (Nasdaq: NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group ("Menarini"), a privately-held,...
-
Karyopharm Therapeutics Misses Q4 EPS by 8c
Karyopharm Therapeutics (NASDAQ:KPTI) reported Q4 EPS of ($0.43), $0.08 worse than the analyst estimate of ($0.35). Revenue for the quarter came in at $33.6 million versus the consensus...
-
Karyopharm earnings missed by $0.08, revenue fell short of estimates
Investing.com - Karyopharm (NASDAQ: KPTI) reported fourth quarter EPS of $-0.43, $0.08 worse than the analyst estimate of $-0.35. Revenue for the quarter came in at $33.6M versus the...
-
Today's most important initiations
By Davit Kirakosyan BMO Capital initiated coverage on Allstate (NYSE:ALL) with an Outperform rating. Shares plunged more than 5% today following the company’s reported preliminary Q4...
-
Karyopharm Earnings beat, Revenue misses In Q3
Investing.com - Karyopharm reported on Monday third quarter {{erl-42593||earnings that beat analysts' forecasts and revenue that fell short of expectations. Karyopharm announced earnings...
-
Karyopharm Therapeutics Tops Q2 EPS by 1c; Offers FY22 Revenue Guidance
Karyopharm Therapeutics (NASDAQ:KPTI) reported Q2 EPS of ($0.62), $0.01 better than the analyst estimate of ($0.63). Revenue for the quarter came in at $39.7 million versus the consensus...
-
Karyopharm Therapeutics Tops Q1 EPS by 10c
Karyopharm Therapeutics (NASDAQ:KPTI) reported Q1 EPS of ($0.53), $0.10 better than the analyst estimate of ($0.63). Revenue for the quarter came in at $47.7 million versus the consensus...
-
U.S. shares higher at close of trade; Dow Jones Industrial Average up 1.79%
Investing.com – U.S. equities were higher at the close on Wednesday, as gains in the Basic Materials, Financials and Oil & Gas sectors propelled shares higher. At the close in NYSE, the Dow...
-
U.S. shares higher at close of trade; Dow Jones Industrial Average up 5.09%
Investing.com – U.S. equities were higher at the close on Monday, as gains in the Utilities, Telecoms and Technology sectors propelled shares higher. At the close in NYSE, the Dow Jones...
-
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.70%
Investing.com – U.S. equities were higher at the close on Friday, as gains in the Technology, Telecoms and Healthcare sectors propelled shares higher. At the close in NYSE, the Dow Jones...
-
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.36%
Investing.com – U.S. equities were lower at the close on Thursday, as losses in the Financials, Basic Materials and Industrials sectors propelled shares lower. At the close in NYSE, the Dow...
-
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.25%
Investing.com – U.S. equities were higher at the close on Tuesday, as gains in the Oil & Gas, Utilities and Telecoms sectors propelled shares higher. At the close in NYSE, the Dow Jones...
-
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.26%
Investing.com – U.S. equities were lower at the close on Tuesday, as losses in the Utilities, Consumer Goods and Oil & Gas sectors propelled shares lower. At the close in NYSE, the Dow...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
